Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients

Introduction. Retrospective observational data show that ACE-inhibitor therapy delays renal failure and improves life expectancy in Alport patients with proteinuria. The EARLY PRO-TECT Alport trial assesses the safety and efficacy of early therapy onset with ramipril in pediatric Alport patients. Me...

Descripción completa

Detalles Bibliográficos
Autores principales: Gross, Oliver, Friede, Tim, Hilgers, Reinhard, Görlitz, Anke, Gavénis, Karsten, Ahmed, Raees, Dürr, Ulrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scholarly Research Network 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395192/
https://www.ncbi.nlm.nih.gov/pubmed/22811928
http://dx.doi.org/10.5402/2012/436046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395192/
https://www.ncbi.nlm.nih.gov/pubmed/22811928
http://dx.doi.org/10.5402/2012/436046

Ejemplares similares